Vir Biotechnology, Inc. (VIR): Shareholders' Equity
$765.28M
As of 2025-12-31
$982.49M
As of 2026-06-30
-28.3%
3-year compound annual growth
+1.3%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $765.28M | -33.5% | 2026-02-23, Balance as of period end |
| 2024-12-31 | $1.15B | -27.7% | 2026-02-23, Balance as of period end |
| 2023-12-31 | $1.59B | -23.5% | 2026-02-23, Balance as of period end |
| 2022-12-31 | $2.08B | +45.1% | 2025-02-27, Balance as of period end |
| 2021-12-31 | $1.43B | +99.7% | 2024-02-26, Balance as of period end |
| 2020-12-31 | $716.85M | +69.1% | 2023-02-28, Balance as of period end |
| 2019-12-31 | $423.94M | n/m | 2022-02-28, Balance as of period end |
| 2018-12-31 | -$179.18M | n/m | 2021-02-25, Balance as of period end |
| 2017-12-31 | -$68.92M | n/a | 2020-03-26, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $765.28M | -33.5% |
| Black Diamond Therapeutics, Inc. (BDTX) | 2025-12-31 | $112.21M | +34.7% |
| Compugen Ltd (CGEN) | 2025-12-31 | $102.73M | +87.1% |
| Recursion Pharmaceuticals, Inc. (RXRX) | 2025-12-31 | $1.13B | +9.3% |
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | $178.13M | -58.3% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $3.94M | +4.4% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | -$5.79M | n/m |
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | $505.66M | -1.0% |
| Invivyd, Inc. (IVVD) | 2025-12-31 | $241.54M | +257.6% |
Compare VIR, BDTX, CGEN, RXRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗